No definite difference for primary endpoint but proven safety with ARNI in MI patients - PACE-CME

No definite difference for primary endpoint but proven safety with ARNI in MI patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Can targeting of IL-6 lead to CV protection in CKD?
Can targeting of IL-6 lead to CV protection in CKD?
ACC.21
Can targeting of IL-6 lead to CV protection in CKD?
- Paul Ridker, MD
No superiority with NOAC compared to standard care following TAVI
No superiority with NOAC compared to standard care following TAVI
ACC.21
No superiority with NOAC compared to standard care following TAVI
- Jean-Philippe Collet, MD, PhD
A call to solve the controversy on omega-3FAs trials
A call to solve the controversy on omega-3FAs trials
ACC.21
A call to solve the controversy on omega-3FAs trials
- Prof. Eileen Handberg, PhD
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
ACC.21
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
- Prof. Freek Verheugt, MD